Recombinant Human IFNAR2/IFNABR Protein (His Tag)(Active)
Size: 100μg
Catalogue Number: PKSH031651-100
Citations, Manuals and MSDS Available upon request.
Abbreviation: IFNAR2; IFNABR
Target Symptom: IFN-alpha-REC; IFN-R; IFNABR; IFNARB
Research Area: Signal Transduction; Cancer; epigenetics and nuclear signal; immunology;
Target Species: Human
Expression Host: HEK293 Cells
Application: Cell culture
Fusion Tag: C-His
Accession: NP_997468.1
Background: Interferon-alpha/beta receptor beta chain (IFNAR2) is a type I membrane protein that forms one of the two chains of a receptor for interferons alpha and beta. Binding and activation of the receptor stimulates Janus protein kinases; which in turn phosphorylate several proteins; including STAT1 and STAT2. Initial cell-surface IFNAR2 expression at diagnosis assessed by flow cytometry widely distributed but showed overall significantly higher expression in CML patients when compared with normal controls. In 15 fresh patients who subsequently received IFNα therapy; IFNAR2 expression at diagnosis was significantly higher in cytogenetic good responders than in poor responders. Down-regulation of IFNAR2 expression during IFNα therapy was observed only in good responders but not in poor responders. The encoded protein also functions as an antiviral factor. IFNAR2 may associate with IFNAR1 to form the type I interferon receptor. This protein serves as a receptor for interferons alpha and beta. IFNAR2 is also involved in IFN-mediated STAT1; STAT2 and STAT3 activation. Isoform 1 and isoform 2 are directly involved in signal transduction due to their association with the TYR kinase; JAK1. Isoform 3 is a potent inhibitor of type I IFN receptor activity. Following binding of IFNα 2; IFNAR2 is internalized; but; instead of being routed towards degradation as it is when complexed to IFNβ ; it recycles back to the cell surface.
Activity: Measured by its ability to inhibit rh IFNβ mediated protection of WISH Human amnion cells infected with vesicular stomatitis virus (VSV) to viral lysis. The EC50 for this effect is typically 1-4μg/mL.
Sequence: Met 1-Lys 243
Purity: > 95 % as determined by reducing SDS-PAGE.
Formulation: Lyophilized from sterile PBS, pH 7.4
Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the printed manual.
Reconstitution: Please refer to the printed manual for detailed information.
Endotoxin: < 1.0 EU per μg of the protein as determined by the LAL method.
Calculated MW: 26.2 kDa
Observed MW: 45 kDa
Storage: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80℃. Reconstituted protein solution can be stored at 4-8℃ for 2-7 days. Aliquots of reconstituted samples are stable at < -20℃ for 3 months.
Shipping: This product is provided as lyophilized powder which is shipped with ice packs.
Research Use Only